Protease-Activatable Bispecific Molecules for Targeted T Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific molecules used in T cell-mediated immunotherapy often activate T cells non-specifically, leading to toxicity in both target and non-target cells, as they do not require proximity to the target cell for activation, which can result in damage to healthy tissues.
Innovation Solution
Development of protease-activatable T cell activating bispecific molecules with a masking moiety that conceals the CD3-binding site until proximity to a target cell is achieved, utilizing a protease-cleavable linker to reveal the binding site only in the presence of a specific protease expressed by the target cell, such as tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific molecules are designed to bind CD3 and target cell antigen simultaneously, then T cell activation and tumor cell lysis are achieved, but non-specific activation occurs leading to toxicity in healthy tissues
Solution Approach 1:
The patent applies preliminary action by pre-concealing the CD3-binding site with a masking moiety before the molecule reaches the target site. The molecule is prepared in an inactive state where the masking moiety blocks CD3 binding, and only becomes active after protease-mediated cleavage occurs at the target tissue location, thus preventing premature activation and systemic toxicity
Solution Approach 2:
The patent uses a masking moiety as an intermediary element that temporarily prevents CD3 binding. This masking moiety is connected via a protease-cleavable linker, creating a controlled release mechanism where the intermediary is removed only under specific conditions (protease presence at target site), enabling selective activation
2Reliability
If a masking moiety is introduced to conceal the CD3-binding site, then specificity is improved, but device complexity increases due to additional components
Solution Approach 1:
The patent merges multiple functions into a single integrated molecule: the bispecific molecule combines target antigen binding, CD3 binding, and self-maskung capabilities in one construct. The masking moiety is covalently attached to the molecule itself, creating an autonomous system that manages its own activation state without requiring separate control mechanisms
Solution Approach 2:
The patent implements a nested structure where the masking moiety is embedded within or attached to the bispecific molecule framework. The protease-cleavable linker acts as a nested element that connects the masking function to the rest of the molecule, allowing sequential unfolding or activation of functional elements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures selective activation of T cells only in the presence of target cells, reducing toxicity to healthy tissues by maintaining T cell inactivity until the molecule is activated near the tumor, thereby enhancing the specificity and efficacy of cancer therapy.
Implementation Method 1
utilizing a protease-cleavable linker to reveal the binding site only in the presence of a specific protease expressed by the target cell
Data Source
AI summary
The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.